Master Alliance Provisions Guide (MAPGuide)

US Department of Defense – Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement

  • Information & materials sharing | Dissemination of Results

<p><span style=”textdecoration: underline;”><b>VIII. Publication and Academic Rightsb><span style=”fontweight: 400;”> span>span>p>
<p><b>VI11.1 Use of Information.b><span style=”fontweight: 400;”> Janssen shall have the right to publish or otherwise disclose information and/or data generated under the Project. Janssen shall include an appropriate acknowledgement of the funding of the Project by the Government in any publication. Notwithstanding the above, the Parties shall not be deemed authorized by this paragraph, alone, to disclose any Confidential Information of another Party to this Project Agreementspan>p>
<p><b>VIII.2 Publication or Public Disclosure of Data Review and Approval of Data for Public Releaseb>p>
<p><span style=”fontweight: 400;”>(1) At least 30 days prior to the scheduled release date, Janssen shall submit to the AOR a copy of the Data to be releasedspan>p>
<p><span style=”fontweight: 400;”>(2) An acknowledgment similar to the following shall be required in any publication of any Data, based or developed under this Project Agreement: &#8220;Effort funded in part by the U.S. Government under P00081 Modification to Other Transaction Number W150KN1691002 between the Janssen Pharmaceuticals, Inc., MCDC, and the Government.&#8221span>p>
<p><span style=”fontweight: 400;”>(3) Parties to this Project Agreement are also responsible for assuring that every publication of material funded under this project contains the following disclaimer: &#8220;The views and conclusions contained herein are those of the authors and do not be represent the official policies or endorsements, either expressed or implied, of the U.S. Government.&#8221; span>p>